EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Canagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK–OPG–CTGF axis

Akihisa Adachi, Hiroyuki Kato, Akihisa Kato, Michihiro Yoshida, Yasuki Hori, Tadashi Toyohara, Kayoko Oda, Yusuke Kito, Kenji Urakabe, Toshitaka Mori, Satoru Takahashi, Hiromi Kataoka

Pancreatology · 2026-08 · 26 (5) · 686-698

DOI: 10.1016/j.pan.2026.05.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pancreatology, 2026-08. Verfasst von Akihisa Adachi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan. Hauptthemen laut MEDLINE: Pancreatitis, Chronic, Canagliflozin, Connective Tissue Growth Factor, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Manpei Suzuki International Prize for Diabetes Research, Terumo Foundation for Life Sciences and Arts.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatitis, ChronicCanagliflozinConnective Tissue Growth FactorSodium-Glucose Transporter 2 InhibitorsPancreasAMP-Activated Protein KinasesAnimalsHumansFibrosisMice, Inbred C57BLMiceMalePancreatic Stellate Cells

Stichwörter der Autor:innen

CanagliflozinChronic pancreatitisFibrosisOsteoprotegerin

Substanzen

CanagliflozinConnective Tissue Growth FactorSodium-Glucose Transporter 2 InhibitorsAMP-Activated Protein KinasesCCN2 protein, mouse

Autor:innen und Institutionen

  • Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan.
  • Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan.
  • Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan. Electronic address: akihisa@med.nagoya-cu.ac.jp.

Förderung

  • Japan Society for the Promotion of Science
  • Manpei Suzuki International Prize for Diabetes Research
  • Terumo Foundation for Life Sciences and Arts
  • Mitsubishi Tanabe Pharma Corporation

Zitieren

APA

Adachi, A., Kato, H., Kato, A., Yoshida, M., Hori, Y., Toyohara, T., Oda, K., Kito, Y., Urakabe, K., Mori, T., Takahashi, S., & Kataoka, H. (2026). Canagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK–OPG–CTGF axis. Pancreatology, 26(5), 686-698. https://doi.org/10.1016/j.pan.2026.05.006

Vancouver

Adachi A, Kato H, Kato A, Yoshida M, Hori Y, Toyohara T, et al. Canagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK–OPG–CTGF axis. Pancreatology. 2026;26(5):686-698. doi:10.1016/j.pan.2026.05.006

BibTeX
@article{Adachi2026,
  author = {Adachi, Akihisa and Kato, Hiroyuki and Kato, Akihisa and Yoshida, Michihiro and Hori, Yasuki and Toyohara, Tadashi and Oda, Kayoko and Kito, Yusuke and Urakabe, Kenji and Mori, Toshitaka and Takahashi, Satoru and Kataoka, Hiromi},
  title = {Canagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK–OPG–CTGF axis},
  journal = {Pancreatology},
  year = {2026},
  volume = {26},
  number = {5},
  pages = {686--698},
  doi = {10.1016/j.pan.2026.05.006}
}
Kostenlos starten →